key: cord-0920801-f9074gyf
authors: Chinitz, Jason S.; Goyal, Rajat; Harding, Melissa; Veseli, Granit; Gruberg, Luis; Jadonath, Ram; Maccaro, Paul; Gandotra, Puneet; Ong, Lawrence; Epstein, Laurence M.
title: Brady‐arrhythmias in Patients with COVID‐19: Marker of Poor Prognosis?
date: 2020-08-21
journal: Pacing Clin Electrophysiol
DOI: 10.1111/pace.14042
sha: c964acee671804935824b44613c7a35caa16ee0c
doc_id: 920801
cord_uid: f9074gyf

BACKGROUND: Despite descriptions of various cardiovascular manifestations in patients with COVID‐19, there is a paucity of reports of new onset brady‐arrhythmias, and the clinical implications of these events are unknown. METHODS: Seven patients presented with or developed severe brady‐arrhythmias requiring pacing support during the course of their COVID‐19 illness over a six‐week period of peak COVID‐19 incidence. A retrospective review of their presentations and clinical course was performed. RESULTS: Symptomatic high degree heart block was present on initial presentation in 3 of 7 patients (43%), and 4 patients developed sinus arrest or paroxysmal high degree AV block. No patients in this series demonstrated left ventricular systolic dysfunction or acute cardiac injury, whereas all patients had elevated inflammatory markers. In some patients, brady‐arrhythmias occurred prior to the onset of respiratory symptoms. Death from complications of COVID‐19 infection occurred in 57% (4/7) during the initial hospitalization, and in 71% (5/7) within three months of presentation. CONCLUSIONS: Despite management of bradycardia with temporary (3/7) or permanent leadless pacemakers (4/7), there was a high rate of short‐term morbidity and death due to complications of COVID‐19. The association between new‐onset brady‐arrhythmias and poor outcomes may influence management strategies for acutely ill patients with COVID‐19. This article is protected by copyright. All rights reserved

Coronavirus 2019 , and with it a concern for a higher mortality. 1 Recent reports have described acute cardiac injury, 2,3 cardiogenic shock, 3 electrocardiographic (ECG) changes, 1,4 right ventricular dysfunction, 5 thromboembolic complications, 6 and tachyarrhythmias. 7 Ventricular arrhythmias have been reported as the first clinical manifestation of COVID-19. 8 However, reports of severe brady-arrhythmias have been rare, mostly anecdotal, and likely under-reported. 9 The clinical implications of new onset brady-arrhythmias in patients with COVID-19 are unknown, and the approach to management is debatable without understanding short-and long-term outcomes, and the risk to health care providers involved with urgent invasive procedures.

Herein we report 7 cases of patients admitted to our health system in Suffolk County, New York during the initial six-week period of peak COVID-19 incidence, who presented with or developed severe brady-arrhythmias during hospitalization. The management strategies and short-term outcomes including in-hospital mortality are described.

We included all patients with confirmed COVID-19 admitted March 15 -April 30, 2020, to two affiliated hospitals who required pacing support for severe bradycardia. Patients were excluded if their bradycardia required only medication adjustment, was identified only at the time of death, or if an alternate etiology of bradycardia was suspected. Clinical data was obtained from the electronic medical record. All testing and treatment, including permanent and temporary pacemaker implantations, were performed at the discretion of the treating physicians.

The Northwell Health Institutional Review Board approved this case series as minimal-risk research using data collected for routine clinical practice and waived the requirement for informed consent. The initial characteristics of 5700 patients from Northwell are presented elsewhere; 2 this case series presents in-depth cardiac results not in that article.

Between March 15 and April 30, 2020, seven patients with confirmed COVID-19 and severe bradycardia requiring acute intervention were retrospectively identified. Demographic and clinical characteristics of these patients are shown in Table 1 . An overview of each patient's presentation and clinical course are presented in Table 2 .

Symptomatic high degree heart block was present on initial presentation in 3 of 7 patients (43%); in two patients, respiratory symptoms developed later in their hospitalization (despite chest radiography suggestive of viral pneumonia at presentation) and the diagnosis of COVID-19 was made after permanent pacemaker implantation (Figure 1 ). Four patients developed sinus arrest or paroxysmal high degree atrioventricular (AV) block lasting between 10-37 seconds documented on inpatient telemetry.

No patients in this series had preexisting cardiac disease. No significant QT prolongation was noted at baseline or during hospitalizations, though preexisting conduction disease was present in 3 patients. Echocardiography performed during hospitalization, or within 6 months prior, revealed normal left ventricular systolic function in all patients (left ventricular ejection fraction 67.5% ±14.3%). Severe pulmonary hypertension and/or right ventricular dysfunction was identified in two patients. There was no evidence of acute coronary syndrome or documented thromboembolism. Respiratory symptoms and radiographic evidence of viral pneumonia were ultimately present in all patients.

Laboratory findings demonstrated significantly elevated inflammatory markers in all patients. No significant electrolyte or thyroid function abnormalities were observed. Cardiac troponin levels (measured with the Roche troponin T assay) were normal in three patients (≤0.01 ng/mL), not measured in two patients, and mildly elevated in two patients who both had concomitant renal insufficiency: patient #1 had ESRD and peak troponin 0.23 ng/mL, and patient #5 had a peak troponin of 0.17 ng/mL in the setting of acute renal failure and peak creatinine >6 mg/dl) ( Table 1) . No patients demonstrated ischemic ECG changes apart from bradycardia or conduction disturbances. Two patients received new rate-slowing medication prior to the brady-arrhythmia events, however, this was not considered to be the primary factor precipitating bradycardia in either case. Five patients received hydroxychloroquine during their hospitalization, four prior to their first recorded bradycardia episode.

Due to perceived life-threatening bradycardia, all patients received temporary (3/7) or permanent pacemakers (4/7). One patient (patient #5) who received a temporary pacemaker after the initial bradycardia event subsequently received a leadless pacemaker due to recurrent bradycardia. In all five patients receiving permanent pacemakers, a leadless pacemaker (Medtronic Micra®) was implanted. No operating staff involved in these procedures subsequently developed COVID-19.

Mortality in this cohort was high, as 5/7 (71%) patients died within three months following admission. Four of the seven patients (57%) died during the initial hospitalization, occurring 17.3 +/-12.5 days following admission and 8.3 +/-10.7 days after the first identified brady-arrhythmia. All mortalities were considered complications of COVID-19 infection, including three patients with hypoxemic respiratory failure, and one who developed fevers, lethargy and hypoglycemia prior to expiration, presumed to be due to COVID-19 sepsis. Another patient had a prolonged hospital course with multisystem organ failure ultimately requiring tracheostomy and feeding tube placement, and suffered further complications following discharge to a long-term care facility prompting withdrawal of supportive care and subsequent expiration on day 90 following initial hospital admission. In the two patients who survived, one had an acute stroke and the other had transient severe encephalopathy during their hospitalizations.

In this series of 7 patients with COVID-19 and severe brady-arrhythmias, short-term mortality and morbidity was high, despite prompt management of bradycardia with pacing support. All patients had elevation of inflammatory markers and multisystem organ involvement, without acute cardiac injury or associated cardiomyopathy. In some patients, brady-arrhythmias presented prior to the onset of respiratory symptoms.

The mechanism of cardiac involvement during COVID-19 remains speculative. Acute bradycardia may be due to direct SARS-CoV-2 infiltration of myocardial cells and the dedicated conduction system, aggravation of pre-existing conduction disease during acute illness, pulmonary injury leading to hypoxia and secondary bradycardia, or collateral damage from inflammatory system activation and cytokine storm. 10 SARS-CoV-2 may also activate the ACE2 receptor, 10 as ACE2 expression has been demonstrated specifically in sino-atrial nodal cells, 11 and ACE2 overexpression has been associated with conduction disturbances. 12 In addition, the SARS-CoV virus causing the 2002 outbreak was associated with sinus bradycardia in up to 15% of patients. 10, 13 Adverse effects of medications, including chloroquine and hydroxychloroquine, may also contribute to conduction system dysfunction. Long-term chloroquine use has been shown to increase Purkinje fiber refractory period and action potential duration, resulting in AV nodal and infra-Hisian conduction disturbance, 14 most commonly fascicular block. 15 Five patients in this series were treated with hydroxychloroquine, though this treatment preceded the development of bradycardia in only four.

All patients received temporary or permanent pacing. A leadless pacemaker was implanted in all patients clinically deemed to require permanent pacing. Leadless pacemaker implantation may be an attractive option in patients with active COVID-19, as the risk of cardiac and intravascular infection may be lower, and the risk of viral transmission to operating staff may be mitigated by the percutaneous approach. However, despite pacing support, outcomes were poor, with 4/7 patients dying during initial hospitalization, and 5/7 dying within three months due to complications of COVID-19.

Brady-arrhythmias may occur as part of the clinical course in patients with COVID-19. In our experience, acute bradycardia was associated with elevation of inflammatory markers and high short-term mortality rates, despite lack of co-existent cardiomyopathy or acute cardiac injury. Management decisions and resource allocation should take into account the potential for adverse outcomes regardless of invasive pacing support, as well as potential risks to health care staff during intervention on these acutely ill patients. 

Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China

Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the

Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China

ST-Segment Elevation in Patients with Covid-19 -A Case Series

Right Ventricular Dilation in Hospitalized Patients with COVID-19 Infection

COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Cardiac involvement in a patient with coronavirus disease 2019 (COVID-19)

Heart break-an unusual cardiac manifestation of coronavirus disease 2019 (COVID-19)

Cardiac and arrhythmic complications in patients with COVID-19

The angiotensin-(1-7)/Mas receptor axis is expressed in sinoatrial node cells of rats

Angiotensin-converting enzyme II in the heart and the kindey

Cardiovascular complications of severe acute respiratory syndrome

Chloroquine-induced cardiomyopathy

Heart conduction disorders in long-term treatment with chloroquine: two new cases

 (5) Death (7)